review · International Journal of Pharmaceutics X
Lipid nanocarriers are increasingly promising vehicles for delivering therapeutic molecules, yet their transition to industrial production remains hindered by strict quality standards and reproducibility issues. High failure rates during research and development frequently stem from immature bottom-up manufacturing techniques, which limit the control over critical quality attributes. To overcome these barriers, pharmaceutical development is turning toward quality by design principles. This methodology focuses on defining the target product profile, evaluating potential formulation risks, and monitoring key variables such as active ingredients, excipients, and manufacturing processes throughout the drug life cycle. Implementing quality by design aids in resolving scale-up challenges, ensuring robust product consistency, and securing regulatory flexibility. By systematically linking product formulation with manufacturing processes, this approach establishes a structured path to translate lipid nanocarriers from laboratory experiments into reliable industrial-scale production.
Lipid nanocarriers hold substantial potential for delivering therapeutic treatments, but inconsistent manufacturing methods often prevent promising medicines from reaching patients. Incorporating quality by design methodologies addresses production failures early, ensuring that advanced drug delivery systems can be reproduced reliably at an industrial scale. This systematic focus on product quality and manufacturing risks supports more efficient transitions from laboratory discoveries to approved therapies.
This work outlines practical guidance for pharmaceutical manufacturers and formulation scientists seeking to scale up lipid nanocarrier production. By applying quality by design to systematically manage ingredients, excipients, and processing variables, organisations can reduce batch failure rates and improve regulatory compliance. The guidance targets the transition phase between laboratory formulation and industrial-scale manufacturing, addressing operational challenges that directly influence commercial feasibility.
AI-generated from the published abstract. Always read the original work before citing.
Lipid nanocarriers have attracted a great deal of interest in the delivery of therapeutic molecules. Despite their many advantages, compliance with quality standards and reproducibility requirements still constrain their industrial production. The relatively high failure rate in lipid nanocarrier research and development can be attributed to immature bottom-up manufacturing practices, leading to suboptimal control of quality attributes. Recently, the pharmaceutical industry has moved toward quality-driven manufacturing, emphasizing the integration of product and process development through the principles of quality by design. Quality by design in the pharmaceutical industry involves a thorough understanding of the quality profile of the target product and involves an assessment of potential risks during the design and development phases of pharmaceutical dosage forms. By identifying essential quality characteristics, such as the active ingredients, excipients and manufacturing processes used during research and development, it becomes possible to effectively control these aspects throughout the life cycle of the drug. Successful commercialization of lipid nanocarriers can be achieved if large-scale challenges are addressed using the QbD approach. QbD has become an essential tool because of its advantages in improving processes and product quality. The application of the QbD approach to the development of lipid nanocarriers can provide comprehensive and remarkable knowledge enabling the manufacture of high-quality products with a high degree of regulatory flexibility. This article reviews the basic considerations of QbD and its application in the laboratory and large-scale development of lipid nanocarriers. Furthermore, it provides forward-looking guidance for the industrial production of lipid nanocarriers using the QbD approach.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.ijpx.2024.100266
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
